Guadecitabine sodium is under clinical development by Astex Pharmaceuticals and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According to GlobalData, Phase II drugs for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Guadecitabine sodium LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Guadecitabine sodium overview
Guadecitabine sodium (SGI-110) is under development for the treatment of melanoma, non-small cell lung cancer, unresectable and metastatic conventional chondrosarcoma, relapsed/refractory and treatment-naive acute myeloid leukemia (AML), solid tumors including muscle-invasive bladder cancer, epithelial ovarian cancer, small-cell lung cancer, primary peritoneal carcinomatosis, fallopian tube cancer, metastatic colorectal cancer, T-cell non-Hodgkin lymphoma. The drug candidate is administered subcutaneously. It acts by targeting DNA methyltransferase 1. The drug candidate utilizes prodrug technology. It was also under development for hepatocellular carcinoma, metastatic melanoma, myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and relapsed/refractory germ cell tumors.
Astex Pharmaceuticals overview
Astex Pharmaceuticals, a subsidiary of Otsuka Holdings Co Ltd, is a drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. The company’s proprietary fragment-based drug discovery platform, Pyramid delivers high-quality and customized drug leads across a variety of therapeutic targets and disease areas. Its pipeline product and programs include DNMT inhibitor, Oral DNMT inhibitor, dual IAP antagonist, oral murine double minute 2 (MDM2) antagonist and extracellular signal-related protein kinases inhibitor. It is also advancing several of its compounds into clinical trials in collaboration with Novartis, AstraZeneca, GSK, and Janssen. The company operates as a subsidiary of Otsuka Pharmaceutical Co Ltd. Astex Pharmaceuticals is headquartered in Pleasanton, California, the US.
For a complete picture of Guadecitabine sodium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
